COVID-19

NVX-CoV2373 was evaluated in adolescents aged 12 to 17 years.

The FDA meeting to discuss extending the Pfizer/BioNTech EUA to children aged 6 months to 4 years has been postponed until data on a third dose has been studied.

The safety of the Pfizer/BioNTech COVID-19 vaccine in pregnant women, for both mother and baby, has been dependent on observation during the rollout. A large population trial provides further support for the vaccine’s safety.

As respiratory viruses and COVID-19 variants lurk seemingly everywhere, here’s how best to detect and differentiate.

A third dose of an mRNA COVID-19 vaccine was safe and associated with modestly increased levels of antibodies in patients with reduced protective humoral immunity before reimmunization.

COVID-19 updates and news to know as of February 7, 2022.

Pfizer received an emergency use authorization (EUA) for Paxlovid, an oral pill for the treatment of mild to moderate COVID-19 in certain adult and pediatric populations.

Several institutions have published guidance on how to treat patients hospitalized with COVID-19.

Spikevax is now the second COVID-19 vaccine approved by regulators.

NVX-CoV2373 is a protein-based COVID-19 vaccine for adults 18 years and older.

COVID-19 updates and news to know as of January 31, 2022.

Further research is needed to determine causation.

A retrospective cohort study in a research letter published in the Journal of the American Academy of Dermatology examined the risk between atopic dermatitis and COVID-19 risk.

First time outpatient visits for mental health services were sharply increased compared with the period before the pandemic.

The COVID-19 vaccine protects against disease and severe effects, but can it help reduce the risk of multisystem inflammatory syndrome in children (MIS-C)?

Some evidence suggests that people with HIV may be more likely to develop a severe case of COVID-19 and antiretroviral therapy may provide some protection against infection.

CMS and state officials are using payment incentives, data collection and program requirements to start edging the lofty ideals of health equity toward reality.

The monoclonal antibody was conditionally recommended for the treatment of mild to moderate COVID-19 in patients at high risk of hospitalization.

With increased infectivity of Omicron, the CDC has updated the guidance on the best mask types to use.

Spending may have reached $130 million despite a lack of evidence that ivermectin effectively treats COVID-19.

COVID-19 updates and news to know as of January 17, 2022.

Employee mandate would have impacted 84 million workers. Healthcare mandate affects every facility that receives federal funding.

A global study examines how often severe outcomes occur within 14 days of a positive COVID-19 test occurring in an emergency department (ED).

But protection against hospitalization and death remain strong.

Since the COVID-19 vaccinations have been approved, there have been numerous trials that have all concluded that vaccines are safe for people with HIV.

COVID-19 updates and news to know as of January 11, 2022.

Do no harm, even though your patient might.

As the need for rapid tests increase, the nation's largest non-profit patient safety organization evaluated seven COVID-19 rapid tests and found serious gaps in their usability.

The Centers for Disease and Control and Prevention (CDC) has given their support for giving a COVID-19 booster to children aged 12 to 15 years.

As trusted source of information for parents, pharmacists are a key part of the plan to distribute the COVID-19 vaccine to newly eligible children.